1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Adragos Pharma Acquires Swiss-Based Sterile Fill-Finish Expert, iBaccinex

27 Nov 2024
Admin
News Article

Adragos Pharma Acquires Swiss-Based Sterile Fill-Finish Expert, iBaccinex

Overview

Adragos Pharma, a global pharmaceutical contract development and manufacturing organization (CDMO) headquartered in Munich, Germany, has acquired Baccinex, a Swiss-based expert in aseptic fill-finish manufacturing. This acquisition significantly enhances Adragos’ sterile manufacturing capabilities and marks a pivotal step in the expansion of its global network.

About Baccinex

Baccinex, based in Courroux, Jura, Switzerland, brings over 20 years of experience in sterile fill-finish processes for both liquid and lyophilized vials.
Operating from its EU-GMP and US FDA-certified facility, Baccinex specializes in clinical trial supplies and small-to-medium scale commercial production, offering world-class quality and reliability to its pharmaceutical clients.

Words from the CEO: Baccinex

Dr. Ursula Bausch, founder and CEO of Baccinex, shared her perspective on the partnership: “Joining Adragos Pharma marks a new chapter for Baccinex. Our shared commitment to quality, innovation, and customer-centric solutions creates an exciting synergy that will enable us to deliver even greater value to our clients worldwide.”

Words from the CEO: Adragos Pharma

Dr. Andreas Raabe, founder and CEO of Adragos Pharma, commented: “The acquisition of Baccinex represents a significant milestone for Adragos. Baccinex’s proven expertise in sterile liquids and lyophilization, combined with its operational excellence, enhances our ability to provide integrated solutions from development through to commercial supply.”
“This addition strengthens our position as a global partner of choice for high-quality pharmaceutical manufacturing.”

Baccinex CEO

Dr. Ursula Bausch will continue to lead Baccinex as CEO, ensuring continuity in operations and leveraging her extensive expertise in sterile manufacturing.
She will also remain a shareholder in the company, reflecting her strong commitment to its continued success as part of Adragos.

The acquisition of Baccinex aligns seamlessly with Adragos’ strategy to build a world-class manufacturing network that provides tailored solutions to meet the evolving needs of its customers.

Legal Advisors for Both the Companies

Pestalozzi Attorneys at Law acted as legal advisor to Adragos Pharma. Capitalmind Investec acted as M&A advisor, and Kellerhals Carrard acted as legal advisor to Dr. Ursula Bausch.

Terms of the transaction remain undisclosed.

About the CDMO: Adragos Pharma

Adragos Pharma is a rapidly growing global CDMO headquartered in Munich, Germany.
With a network of six sites across Europe and Japan, Adragos offers comprehensive pharmaceutical services, supporting clients from development through to commercial production.

About the Other CDMO: Baccinex

Baccinex is a Swiss-based CDMO specializing in aseptic fill-finish services for liquid and lyophilized vials.
With over 20 years of experience, Baccinex operates an EU-GMP and US FDA-certified facility in Courroux, Jura, Switzerland, delivering high-quality pharmaceutical solutions tailored to the unique needs of its clients.